CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 40.32×, higher than 95% of its Biotechnology peers (median 5.5×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.80BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.2580xvs all stocks
52-Week Change
143.26%vs all stocks
Market Capitalization
3.80BUSDvs all stocks (USD)
Enterprise Value
2.65BUSDvs all stocks (USD)
Forward P/E
-21.88xvs Biotechnology peers
Price to Book (MRQ)
6.83xvs Biotechnology peers
Enterprise to EBITDA
-22.89xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-18.86%vs Biotechnology peers
Return on Equity (TTM)
-26.64%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-115.58MUSDvs all stocks (USD)
Net Income (TTM)
-98.78MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-65.47MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-46.08MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-119.66MUSDvs all stocks (USD)
Pre-tax Income
-103.69MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-103.69MUSDFY2025 · Dec 31, 2025EBIT
-119.66MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-119.39MUSDFY2025 · Dec 31, 2025Research & Development
85.86MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
33.80MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.01MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-103.69MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-68.58MUSDFY2025 · Dec 31, 2025Free Cash Flow
-68.63MUSDDerived from operating cash flow minus capital expenditure. This filing charges 263K of depreciation against 55K of capital expenditure, and its own free-cash-flow line reads -70.46M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
98.90MUSDFY2025 · Dec 31, 2025Income Tax Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-103.69MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
263.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
34.02MUSDFY2025 · Dec 31, 2025Other Non-cash Items
353.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
817.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-337.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
55.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-446.79MUSDFY2025 · Dec 31, 2025Sale of Investments
272.90MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-173.84MUSDFY2025 · Dec 31, 2025Other Financing Charges
-217.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
215.95MUSDFY2025 · Dec 31, 2025Shares Outstanding
60.89MSharesUpdated Jul 18, 2026Float Shares
53.27MSharesUpdated Jul 18, 2026Shares Short
8.53MSharesUpdated Jul 18, 2026Short Ratio
3.49daysvs all stocks
Short % of Shares Outstanding
17.39%vs all stocks
% Held by Insiders
6.55%vs all stocks
% Held by Institutions
90.17%vs all stocks
Total Cash (MRQ)
452.40MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.43USDUpdated Jul 18, 2026Total Debt (MRQ)
302.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0007xvs Biotechnology peers
Current Ratio (MRQ)
40.32xvs Biotechnology peers
Book Value per Share (MRQ)
7.45USDUpdated Jul 18, 2026Total Assets
476.17MUSDvs all stocks (USD)
Total Current Assets
474.88MUSDFY2025 · Dec 31, 2025Total Liabilities
16.57MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.29MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
16.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
98.90MUSDFY2025 · Dec 31, 2025Other Short-term Investments
363.73MUSDFY2025 · Dec 31, 2025Accounts Payable
2.16MUSDFY2025 · Dec 31, 2025Short-term Debt
399.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
351.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
59.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-347.17MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
459.60MUSDvs all stocks (USD)
52-Week Low
14.79USDUpdated Jul 18, 202652-Week High
54.10USDUpdated Jul 18, 202652-Week Change
143.26%vs all stocks
Beta
0.2580xvs all stocks
50-Day MA
43.88USDUpdated Jul 18, 2026200-Day MA
30.99USDUpdated Jul 18, 2026Avg 10-Day Volume
907.15KSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.96MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.64USDUpdated Jul 18, 2026Other Income / Expense
-49.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 40.32×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 40.32Industry median: 5.50Industry P95: 22.03Peers compared: 197
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.1×)Notable
Debt-to-equity: 0.00Industry median: 0.10Industry P5: 0.00Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.61
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $3.8B, above the global median of $1.15BNotable
Market cap (USD): 3,800,516,496Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Catalyst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Tiantan Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Duality Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NewAmsterdam Pharma Co. N.V.
Tier 1ProductionApproval-Gated PipelineRule
Denali Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Ather Energy Ltd.
1 interpretationLow-Leverage Liquidity Configuration
Apogee Therapeutics Inc.
1 interpretationLow-Leverage Liquidity Configuration
King Slide Works Co., Ltd.
1 interpretationLow-Leverage Liquidity Configuration